ArrowMark Colorado Holdings LLC Reduces Stock Position in Zenas BioPharma, Inc. $ZBIO

ArrowMark Colorado Holdings LLC lessened its stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO) by 24.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 824,668 shares of the company’s stock after selling 269,670 shares during the period. ArrowMark Colorado Holdings LLC owned approximately 1.54% of Zenas BioPharma worth $18,308,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its holdings in shares of Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock valued at $89,000 after buying an additional 2,679 shares during the period. Geode Capital Management LLC grew its holdings in shares of Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after acquiring an additional 16,461 shares during the period. Intech Investment Management LLC grew its holdings in shares of Zenas BioPharma by 13.9% in the second quarter. Intech Investment Management LLC now owns 13,206 shares of the company’s stock worth $128,000 after acquiring an additional 1,607 shares during the period. Rhumbline Advisers increased its position in Zenas BioPharma by 71.3% during the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after acquiring an additional 8,207 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Zenas BioPharma by 60.8% during the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares during the last quarter.

Zenas BioPharma Price Performance

NASDAQ ZBIO opened at $24.04 on Friday. The business’s fifty day moving average is $22.48 and its 200 day moving average is $27.00. Zenas BioPharma, Inc. has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The company has a market capitalization of $1.29 billion, a PE ratio of -3.40 and a beta of -1.94.

Insider Transactions at Zenas BioPharma

In related news, Director Patricia L. Allen acquired 15,700 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were purchased at an average price of $24.85 per share, with a total value of $390,145.00. Following the completion of the purchase, the director directly owned 15,700 shares of the company’s stock, valued at $390,145. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hongbo Lu acquired 25,985 shares of the stock in a transaction dated Wednesday, February 11th. The shares were bought at an average cost of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the transaction, the director owned 347,968 shares in the company, valued at approximately $7,829,280. This represents a 8.07% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 202,845 shares of company stock valued at $3,747,185 over the last quarter. 16.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Wedbush reissued an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research report on Monday, December 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research report on Tuesday, January 6th. HC Wainwright reiterated a “buy” rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, February 10th. Wall Street Zen raised shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Evercore assumed coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.83.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.